---
title: Baseline Immune State and T-cell Clonal Kinetics are Associated with Durable
  Response to CAR-T Therapy in Large B-cell Lymphoma
date: '2024-09-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39241199/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240907181832&v=2.18.0.post9+e462414
source: Blood
description: Engineered cellular therapy with CD19-targeting chimeric antigen receptor
  T-cells (CAR-T) has revolutionized outcomes for patients with relapsed/refractory
  Large B-Cell Lymphoma (LBCL), but the cellular and molecular features associated
  with response remain largely unresolved. We analyzed serial peripheral blood samples
  ranging from day of apheresis (day -28/baseline) to 28 days after CAR-T infusion
  from 50 patients with LBCL treated with axicabtagene ciloleucel (axi-cel) by integrating
  ...
disable_comments: true
---
Engineered cellular therapy with CD19-targeting chimeric antigen receptor T-cells (CAR-T) has revolutionized outcomes for patients with relapsed/refractory Large B-Cell Lymphoma (LBCL), but the cellular and molecular features associated with response remain largely unresolved. We analyzed serial peripheral blood samples ranging from day of apheresis (day -28/baseline) to 28 days after CAR-T infusion from 50 patients with LBCL treated with axicabtagene ciloleucel (axi-cel) by integrating ...